Venous thromboembolic disease

Obstetrics and Gynecology

Volumn 104, Issue 4 SUPPL., 2004, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ESTROGEN THERAPY; FEMALE; HUMAN; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; VEIN THROMBOSIS;

ANTICOAGULANTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; VENOUS THROMBOSIS;

EID: 16544394670     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000138792.50402.69     Document Type: Article

References (42)

1. Rossouw JE, Anderson GL, Prentice R.L., LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33. (Level I) (Pubitemid 34761611)
2. Hulley S, Grady D, Bush T., Furberg C, Herrington D, Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13. (Level I) (Pubitemid 28502636)
3. Grady D, Wenger NK, Herrington D, Khan S., Furberg C, Hunninghake D, et al Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2000; 132: 689-96. (Level I) (Pubitemid 30244167)
4. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-302. (Level I)
5. Hoibraaten E, Qvigstad E, Arnesen H., Larsen S, Wickstrom E, Sandset PM Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84: 961-7. (Level I) (Pubitemid 32014029)
6. Bauer KA. Hormone replacement therapy and the factor V Leiden mutation. Arterioscler Thromb Vasc Biol 2002; 22: 879-80. (LevelIII) (Pubitemid 34655210)
7. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-35. (Level III) (Pubitemid 32429213)
8. Petitti DB. Clinical practice. Combination estrogen-pro-gestin oral contraceptives [published erratum appears in N Engl J Med 2004; 350: 92]. N Engl J Med 2003; 349: 1443-50. (Pubitemid 37211060)
9. Miller J, Chan BK, Nelson HD Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U. S. Preventive Services Task Force [published erratum appears in Ann Intern Med 2003; 138: 360]. Ann Intern Med 2002; 136: 680-90. (Meta-analysis) (Pubitemid 34462681)
10. Perez Gutthann S., Garcia Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314: 796-800. (Level II-2)
11. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial [published erratum appears in JAMA 1995; 274: 1676]. JAMA 1995; 273: 199-208. (Level I)
12. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 315: 149-53. (Level III) (Pubitemid 27303059)
13. Angerer P, Stork S, Kothny W., Schmitt P, von Schacky C Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001; 21: 262-8. (Level I) (Pubitemid 32125376)
14. Hodis HN, Mack WJ, Lobo R.A., Shoupe D., Sevanian A, Mahrer PR, et al Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Estrogen in the Prevention of Atherosclerosis Trial Research Group. Ann Intern Med 2001; 135: 939-53. (Level I) (Pubitemid 33131615)
15. Anderson GL, Limacher M, Assaf A.R., Bassford T., Beresford SA, Black H, et al Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. The Women's Health Initiative Steering Committee. JAMA 2004; 291: 1701-12. (Level I) (Pubitemid 38489892)
16. Cherry N, Gilmour K, Hannaford P., Heagerty A, Khan MA, Kitchener H, et al Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. ESPRIT team. Lancet 2002; 360: 2001-8. (Level I) (Pubitemid 36026578)
17. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M., Schofiel PM A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Pap-worth HRT atherosclerosis study. BJOG 2002; 109: 1056-62. (Level I) (Pubitemid 35279139)
18. Viscoli CM, Brass LM, Kernan W.N., Sarrel PM, Suissa S, Horwitz RI A clinical trial of estrogen-replacement therapy after ischemic stroke. N EnglJ Med 2001; 345: 1243-9. (Level I) (Pubitemid 34951488)
19. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary athero-sclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002; 288: 2432-40. (Level I) (Pubitemid 35340539)
20. Herrington DM, Reboussin DM, Brosnihan K.B., Sharp PC, Shumaker SA, Snyder TE, et al Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-9. (Level I) (Pubitemid 30650747)
21. Hodis HN, Mack WJ, Azen S.P., Lobo RA, Shoupe D, Mahrer PR, et al Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. N Engl J Med 2003; 349: 535-45 (Level I).
22. Hulley S, Furberg C, Barrett-Connor E, Cauley J., Grady D, Haskell W, et al Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/ Progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66. (Level II-1) (Pubitemid 34705519)
23. Archer DF, Dorin MH, Heine W, Nanavati N., Arce JC Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group. Obstet Gynecol 1999; 94: 323-9. (Level I) (Pubitemid 29393063)
24. Speroff L, Rowan J, Symons J., Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study): a randomized controlled trial. JAMA 1996; 276: 1397-403. (Level I) (Pubitemid 26365845)
25. Sulak PJ, Caubel P, Lane R. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy. Int J Fertil Womens Med 1999; 44: 286-96. (Level I) (Pubitemid 30043395)
26. Utian WH, Shoupe D, Bachmann G., Pinkerton JV, Pickar JH Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 75: 1065-79. (Level I) (Pubitemid 32522600)
27. Surgically confirmed gallbladder disease, venous thrombo-embolism, and breast tumors in relation to postmeno-pausal estrogen therapy. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. N Engl J Med 1974; 290: 15-9. (Level II-2)
28. Daly E, Vessey MP, Hawkins M.M., Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80. (Level II-2) (Pubitemid 26340751)
29. Jick H, Derby LE, Myers M.W., Vasilakis C., Newton KM Risk of hospital admission for idiopathic venous thrombo-embolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-3. (Level II-2) (Pubitemid 26340752)
30. Hoibraaten E, Abdelnoor M, Sandset PM Hormone replacement therapy with estradiol and risk of venous thromboembolism: a population-based case-control study. Thromb Haemost 1999; 82: 1218-21. (Level II-2) (Pubitemid 29473780)
31. Varas-Lorenzo C., Garcia-Rodriguez LA, Cattaruzzi C., Troncon MG, Agostinis L, Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 1998; 147: 387-90. (Level II-2)
32. Devor M, Barrett-Connor E, Renvall M., Feigal D Jr, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-82. (Level II 2)
33. Grodstein F, Stampfer MJ, Goldhaber S.Z., Manson JE, Colditz GA, Speizer FE, et al Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-7. (Level II-2) (Pubitemid 26340753)
34. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. EStrogen and THromboEmbolism Risk Study Group. Lancet 2003; 362: 428-32. (Pubitemid 36999704)
35. Rosendaal FR, Vessey M, Rumley A., Daly E, Woodward M, Helmerhorst F.M., et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002; 116: 851-4. (Level II-2) (Pubitemid 34227006)
36. Herrington DM, Vittinghoff E, Howard T.D., Major DA, Owen J, Reboussin DM, et al Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002; 22: 1012-7. (Level II-2) (Pubitemid 34655232)
37. Coumadin tablets. In: Physicians' desk reference. 58th ed. Montvale (NJ): Thomson PDR; 2004. p. 1048-52. (Level III)
38. Fisher B, Costantino JP, Wickerham D.L., Redmond CK, Kavanah M, Cronin WM, et al Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P1 Study. J Natl Cancer Inst 1998; 90: 1371-88. (Level I) (Pubitemid 28439961)
39. Cuzick J, Powles T, Veronesi U., Forbes J, Edwards R, Ashley S., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296-300. (Meta-analysis) (Pubitemid 36126189)
40. Chlebowski RT, Col N, Winer E.P., Collyar DE, Cum mings SR, Vogel VG 3rd. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group. J Clin Oncol 2002; 20: 3328-43. (Meta-analysis) (Pubitemid 34831530)
41. Cauley JA, Norton L, Lippman M.E., Eckert S., Krueger KA, Purdie DW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. [published erratum appears in Breast Cancer Res Treat 2001; 67: 191]. Breast Cancer Res Treat 2001; 65: 125-34. (Level I) (Pubitemid 32193616)
42. Evista. In: Physicians' desk reference. 58th ed. Montvale (NJ: Thomson PDR; 2004. p. 1804-8. (Level III)